ADVM - Adverum Biotechnologies, Inc.
3
-0.230 -7.667%
Share volume: 372,877
Last Updated: 05-07-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.02%
PREVIOUS CLOSE
CHG
CHG%
$3.23
-0.23
-0.07%
View ratios
| Fiscal Date | 03-31-2023 | 06-30-2023 | 09-30-2023 | 12-31-2023 | 03-31-2024 | 06-30-2024 | 09-30-2024 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 05-09-2024 | 08-10-2023 | 11-09-2023 | 11-04-2024 | 05-09-2024 | 08-12-2024 | 11-04-2024 | |
| Total revenue | 3.600 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 1.000 M | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 3.600 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 1.000 M | |
| -100.00% | nan% | nan% | nan% | inf% | ||||
| Operating expenses | 33.839 M | 33.065 M | 34.529 M | 26.158 M | 26.839 M | 20.882 M | 30.221 M | |
| Selling general and admin | 12.780 M | 12.466 M | 13.789 M | 10.880 M | 11.429 M | 3.785 M | 9.782 M | |
| Research and development | 21.059 M | 20.599 M | 20.740 M | 15.278 M | 15.410 M | 17.097 M | 20.439 M | |
| Total expenses | 33.839 M | 33.065 M | 34.529 M | 26.158 M | 26.839 M | 20.882 M | 30.221 M | |
| -2.29% | 4.43% | -24.24% | 2.60% | -22.20% | 44.72% | |||
| Operating income | -30.239 M | -33.065 M | -34.529 M | -26.158 M | -26.839 M | -20.882 M | -29.221 M | |
| Ebit | -29.039 M | -31.291 M | -32.802 M | -23.988 M | -24.828 M | -18.478 M | -26.893 M | |
| Pretax income | -29.039 M | -31.489 M | -32.868 M | -24.847 M | -24.787 M | -18.476 M | -27.134 M | |
| 8.44% | 4.38% | -24.40% | -0.24% | -25.46% | 46.86% | |||
| Income tax | 17.000 K | 21.000 K | 17.000 K | -1.133 M | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -29.056 M | -31.510 M | -32.885 M | -23.714 M | -24.787 M | -18.476 M | -27.134 M | |
| -8.45% | -4.36% | 27.89% | -4.52% | 25.46% | -46.86% |
